Structured evidence table for Postbiotic Gut Health Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Postbiotic Gut Health Randomized Trial | Additionally, an unusually high bowel movement frequency that does not qualify as diarrhea has been associated with changes in the gut microbiome []. | 4 | Otaru Nize (2026) | A Postbiotic Containing Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii subsp. lactis CNCM I-4831 Reduces Bowel Movement Frequency in Healthy Adults with Self-Reported Unusually Frequent and Soft Stools |
| Postbiotic Gut Health Randomized Trial | However, there was a trend (= 0.053) of increased Shannon diversity for the postbiotic group compared to the placebo (), suggesting a redistribution of taxa abundances. | 4 | Otaru Nize (2026) | A Postbiotic Containing Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii subsp. lactis CNCM I-4831 Reduces Bowel Movement Frequency in Healthy Adults with Self-Reported Unusually Frequent and Soft Stools |
| Postbiotic Gut Health Randomized Trial | Recent population-based research suggests that bowel movement frequency is associated with distinct microbial and metabolomic profiles even among generally healthy adults, suggesting that bowel habits may be a relevant marker of gastrointestinal and systemic physiology beyond clinically diagnosed gastrointestinal disorders []. | 4 | Otaru Nize (2026) | A Postbiotic Containing Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii subsp. lactis CNCM I-4831 Reduces Bowel Movement Frequency in Healthy Adults with Self-Reported Unusually Frequent and Soft Stools |
| Postbiotic Gut Health Randomized Trial | 1 2 Chronic diarrhea is defined as loose or watery stools which occur three or more times within 24 h and last for four or more weeks [], corresponding to ≥21 bowel movements per week. | 4 | Otaru Nize (2026) | A Postbiotic Containing Limosilactobacillus fermentum CNCM I-2998 and Lactobacillus delbrueckii subsp. lactis CNCM I-4831 Reduces Bowel Movement Frequency in Healthy Adults with Self-Reported Unusually Frequent and Soft Stools |
| Postbiotic Gut Health Randomized Trial | The gut-immune-metabolic axis has emerged as a central regulator of human health, with growing evidence indicating that microbiota-derived metabolites improve gut microbial ecology, enhance intestinal barrier integrity, reduce systemic inflammation, and maintain metabolic homeostasis. | 4 | Abbas A (2026) | Postbiotics as Next Generation Biotherapeutics Targeting the Gut-Immune-Metabolic Axis: An Integrative Review. |
| Postbiotic Gut Health Randomized Trial | This review synthesizes current mechanistic and clinical evidence on the role of postbiotics in regulating intestinal barrier integrity, immune responses, oxidative stress, and metabolic-endocrine homeostasis. | 4 | Abbas A (2026) | Postbiotics as Next Generation Biotherapeutics Targeting the Gut-Immune-Metabolic Axis: An Integrative Review. |
| Postbiotic Gut Health Randomized Trial | The literature was identified through the PubMed/MEDLINE, Scopus, and Web of Science, integrating evidence from experimental, mechanistic, animal and clinical studies on the therapeutic potential of postbiotics to modulate the gut-immune-metabolic axis. | 4 | Abbas A (2026) | Postbiotics as Next Generation Biotherapeutics Targeting the Gut-Immune-Metabolic Axis: An Integrative Review. |
Source documents